As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Bicycle Therapeutics plc. The largest reported stake is Armistice Capital, LLC's, at 6.72%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Bicycle Therapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 3,398,000 · Sole dispositive: 0 · Shared dispositive: 3,398,000 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Long Focus Capital Management, LLC · Percent: 6.6% · SCHEDULE 13G
- · Holder: Armistice Capital, LLC · Percent: 6.75% · SCHEDULE 13G/A
- · Holder: Raymond Debbane · Percent: 3.1% · SCHEDULE 13G/A
- · Holder: Westfield Capital Management Company, L.P. · Percent: 0% · SCHEDULE 13G/A
Bicycle Therapeutics plc has 13 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of american depositary shares, each representing one ordinary share, nominal value 0.01 euro per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.72% | 3,398,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Long Focus Capital Management, LLC | 6.6% | 3,310,687 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Point72 Asset Management, L.P. | 3.9% | 1,860,317 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 3.1% | 1,560,882 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 | |
| Deep Track Capital, LP | 2.42% | 1,203,244 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Westfield Capital Management Company, L.P. | 0% | SCHEDULE 13G/A, 2026-03-04 | 2026-02-28 |
Holding shares or following this stake? See who's behind Bicycle Therapeutics plc and the warning signs.
Free to see. No signup.
Keep reading
More on Bicycle Therapeutics plc and the records around it.
Bicycle Therapeutics plc elsewhere on the record
Companies that share a holder
- Westfield Capital Management Company, L.P. also filed stake reports on 2 other companies: IMAX CORP (Jun 2026), Ascendis Pharma A/S (Feb 2026)
- LONG FOCUS CAPITAL MANAGEMENT, LLC also filed stake reports on 8 other companies: AURA BIOSCIENCES, INC. (Aug 2026), STANDARD BIOTOOLS INC. (Aug 2026), ONITY GROUP INC. (May 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Bicycle Therapeutics plc
Get an email when Bicycle Therapeutics plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bicycle Therapeutics plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bicycle Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bicycle Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 3,398,000 | 0 | 3,398,000 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 3,398,000 | 0 | 3,398,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Bicycle Therapeutics plc by CUSIP 088786108 and gives its principal executive office as BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Point72 Asset Management, L.P. | 3.9% | SCHEDULE 13G/A |
| 2025-08-14 | Deep Track Capital, LP | 2.42% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-02-11 | Westfield Capital Management Company, L.P. | 6.04% | SCHEDULE 13G/A |
| 2026-02-18 | Armistice Capital, LLC | 6.48% | SCHEDULE 13G |
| 2026-03-03 | Westfield Capital Management Company, L.P. | 0% | SCHEDULE 13G/A |
| 2026-03-03 | Westfield Capital Management Company, L.P. | 0% | SCHEDULE 13G/A |
| 2026-03-03 | Raymond Debbane | 6.3% | SCHEDULE 13G |
| 2026-03-04 | Westfield Capital Management Company, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-04 | Raymond Debbane | 3.1% | SCHEDULE 13G/A |
| 2026-05-15 | Long Focus Capital Management, LLC | 6.6% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 6.75% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 6.72% | SCHEDULE 13G/A |
Questions about who owns Bicycle Therapeutics plc
Who owns Bicycle Therapeutics plc?
On this page, 2 holders' latest ownership filings report 5% or more of Bicycle Therapeutics plc: Armistice Capital, LLC (6.72%, Schedule 13G/A, filed 2026-08-14) and Long Focus Capital Management, LLC (6.6%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Bicycle Therapeutics plc?
By the share each holder's latest filing reports, the largest holders of Bicycle Therapeutics plc on this page are Armistice Capital, LLC (6.72%) and Long Focus Capital Management, LLC (6.6%).
When did Armistice Capital, LLC buy into Bicycle Therapeutics plc?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 4.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 6.72%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Bicycle Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.